Press Releases
CAESAREA, Israel –(BUSINESS WIRE)– Mazor Robotics Ltd. (TASE: MZOR) (NASDAQ GM: MZOR), a developer of innovative guidance systems and complementary products, announced today that it has sold a second Renaissance system to Westside Surgical Hospital located in Houston, Texas. This represents the third Renaissance system in the Houston area and eighth Renaissance system in the state of Texas. Westside Surgical Hospital is part of the K+S Consulting Group, an owner and operator of hospitals and outpatient surgical centers, including Humble Surgical Hospital, another Renaissance system site.
The Renaissance system will be installed at Westside Surgical Hospital, where renowned orthopedic surgeon, Dr. Richard Francis, regularly operates. It will be the second Renaissance system installed by Westside Surgical and will be used for clinical and training purposes.
“The success of the Renaissance system, which is supported by the number of procedures performed and the business and clinical benefits, is driving increased interest from surgeons and hospital administrators,” commented Ori Hadomi, Mazor’s Chief Executive Officer. “Furthermore, in choosing to add a second system for clinical and training purposes, Westside Surgical sees the future value of Renaissance as it seeks to enhance and broaden surgeon participation.”
Westside Surgical Hospital is a multi-specialty surgical hospital created to serve all people through exemplary healthcare, education and community service. With 12 overnight beds and six operating rooms, Westside Surgical Hospital is equipped to perform a wide range of inpatient and outpatient procedures and specializes in breast, orthopedic and spine surgery, among a wide range of surgical and diagnostic offerings. It performs 4,500 surgical procedures annually, and its mission is to provide the highest quality services in a safe, welcoming and comfortable environment.
About Mazor
Mazor Robotics (TASE: MZOR; NASDAQGM: MZOR) believes in healing through innovation by developing and introducing revolutionary robotic-based technology and products aimed at redefining the gold standard of quality care. Mazor Robotics Renaissance® Guidance System enables surgeons to conduct spine and brain procedures in a more accurate and secure manner. For more information, please visit www.MazorRobotics.com.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other securities laws. Any statements in this release about future expectations, plans or prospects for the Company, including without limitation, statements regarding the expectations for growth in system sales and recurring revenue, the Company’s expected sales in 2016, and other statements containing the words “believes,” “anticipates,” “plans,” “expects,” “will” and similar expressions are forward-looking statements. These statements are only predictions based on Mazor’s current expectations and projections about future events. There are important factors that could cause Mazor’s actual results, level of activity, performance or achievements to differ materially from the results, level of activity, performance or achievements expressed or implied by the forward-looking statements. Those factors include, but are not limited to, the impact of general economic conditions, competitive products, product demand and market acceptance risks, reliance on key strategic alliances, fluctuations in operating results, and other factors indicated in Mazor’s filings with the Securities and Exchange Commission (SEC) including those discussed under the heading “Risk Factors” in Mazor’s annual report on Form 20-F filed with the SEC on April 29, 2015 and in subsequent filings with the SEC. For more details, refer to Mazor’s SEC filings. Mazor undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or to changes in our expectations, except as may be required by law.
U.S. Contacts: EVC Group
Michael Polyviou/Doug Sherk – Investors
mpolyviou@evcgroup.com; dsherk@evcgroup.com
212.850.6020; 646-445-4800
David Schemelia – Media
646.201.5431
Latest Tweet
Mazor #CoreTechnology can help you produce consistent results that lead to improved clinical outcomes. Get more inf… https://t.co/LJDbcI17O1